65,437 trials
Urologic Neoplasms
Primary: Number of Participants With Progression-free Survival at Six Months (PFS6) in Cohort A — 4 Participants
Refractory Multiple Myeloma
Primary: Phase I: Highest Tolerated Low Dose (HTLD) — 50; 50 mg/m^2
Lung Disease
Primary: Count of Participants With Primary Graft Dysfunction (PGD), Grade 3 — 8; 8; 2 Participants
Seasonal Allergic Rhinitis
Primary: Total Nasal Symptom Score (TNSS) — 67.1; 78.0 score on a scale — p=0.391
Smoking · Smoking Cessation · Smoking, Tobacco
Primary: Quit Attempts — 30; 24; 26; 17 Participants
Diabetes Mellitus, Type 2
Primary: Fasting Serum Glucose — 6.6; 7.3; 8.2 mmol/L — p=0.031
Multiple Sclerosis
Primary: Bioequivalence of 20 mg Ofatumumab Injected by Pre-filled Syringe (PFS) vs Autoinjector (AI) to Abdomen as Measured by AUCtau — 487.7; 474.1 h×µg/mL
Intervertebral Disc Degeneration
Primary: Total Consumption of Fentanyl (in Micrograms) Self-administered by the Patient and Accessed at 24 and 48 Hours After Spine Surgery. — 726; 503; 180; 136 micrograms
Intracranial Aneurysms
Primary: Percentage of Participants With Complete Occlusion of the Target Aneurysm and ≤50% Stenosis of the Parent Artery and an Alternative Treatment of the Target Intracranial…
Chemotherapy-induced Nausea and Vomiting · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Number of Participants With Total Protection in the Acute, Delayed and Overall Periods — 22; 14; 11; 5 Participants
Epilepsy
Primary: Patients Satisfaction — 6.33; 6.45 score on a scale
Systemic Lupus Erythematosus · Arthritis
Primary: Arthritis Complete Response — 4; 0 participants
Asthma · Chronic Obstructive Pulmonary Disease
Primary: Inhaler Use Correctness — 3.52 correct steps
Ankylosing Spondylitis
Primary: Proportion of Patients Who Achieved ASAS20 Response in the Pooled Secukinumab Group Compared With the Placebo Group at Week 12 — 72; 31 Participants — p=0.3512
Cystic Fibrosis
Primary: Change in Absolute FEV1 From Baseline Over 26 Weeks — 106.53; 52.38 mL — p=0.059